This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

protocol with reagents supplied in the 10x Genomics Chromium Next Gel Bead-in-Emulsion (GEMs) Single Cell 3′ Kit v3.1. Briefly, the concentrations of nuclei and intact cells in the nuclear preparation ...

Sorted single-cell suspensions were resuspended at an estimated final concentration of 270, 1150 and 1450 cells/μl and loaded on a Chromium GemCode Single Cell Instrument (10x Genomics) to generate ...

Single cell sequencing libraries were prepared using the Chromium Controller (10x Genomics) by following the provided protocol ... of emulsion droplets contain both a cell and a barcoded GEM bead ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.